Oxurion in negotiations to acquire Eclevar, a MedTech specialist

Oxurion, a biopharmaceutical company based in Leuven, Belgium, has announced that it has entered into exclusive negotiations to acquire the operational assets of Eclevar, a French CRO in the MedTech sector. This move is part of Oxurion's objective to expand its platform to include clinical and regulatory services in the life sciences industry.

Eclevar, with an established presence in Europe, Japan, and China, generated €2.9 million in revenue over 14 months. Forecasts for 2027 predict €3 million, illustrating the potential of this acquisition in a growing and regulated market.

The proposed transaction would see Oxurion hold 68% of a new entity incorporating Eclevar, with an contribution of 250,000 euros in working capital.